Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had pressured Regeneron from all-time highs, and the firm sees its current share price at a “particularly attractive entry point, with limited downside risk.” Wolfe adds that its bullish take hinges on belief that in 2025, peer-leading growth, through either successful launches or defensive positioning, will be rewarded.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron initiated with an Outperform at Wolfe Research
- American upgraded, Regeneron initiated: Wall Street’s top analyst calls
- Regeneron initiated with a Neutral at Citi
- Regeneron announces new, updated data from hematology pipeline at ASH
- Regeneron price target lowered to $1,000 from $1,150 at Oppenheimer